In our study we used a human-based ex-vivo organ tissue to assess the effect of IL-13 in comparison to commonly used laboratory animals and in-vitro cell cultures based on clinically relevant endpoints such as mucus hypersecretion, inflammation, and airway hyperresponsiveness. This evidence concerns the gene IL13 and airway hyperresponsiveness.